Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palupiprant - Adlai Nortye

Next Previous
Drug Profile

Palupiprant - Adlai Nortye

Alternative Names: AN-0025; E-7046; TPST-7317

Latest Information Update: 02 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Developer Adlai Nortye; Eisai Inc
  • Class Amides; Antineoplastics; Benzoic acids; Fluorinated hydrocarbons; Phenyl ethers; Pyrazoles; Small molecules
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rectal cancer
  • Phase I Bladder cancer; Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Triple negative breast cancer

Most Recent Events

  • 16 Apr 2025 Rutgers in collaboration with Adlai Nortye withdrew a phase I trial prior to enrolment for Non small cell lung cancer (Combination therapy, Metastatic disease) in USA (PO) (NCT05358691)
  • 24 Jan 2025 Adlai Nortye completes a phase Ia trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04975958)
  • 13 Sep 2024 Efficacy and pharmacokinetics data from a phase Ib trial in Oesophageal cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top